دورية أكاديمية
HIV and neoplasms: What do we know so far?
| العنوان: | HIV and neoplasms: What do we know so far? |
|---|---|
| المؤلفون: | Souza TF; Centro Universitário FMABC, Santo André, SP, Brazil., Sym YV; Centro Universitário FMABC, Santo André, SP, Brazil., Chehter EZ; Centro Universitário FMABC, Santo André, SP, Brazil. |
| المصدر: | Einstein (Sao Paulo, Brazil) [Einstein (Sao Paulo)] 2023 Jun 19; Vol. 21, pp. eRW0231. Date of Electronic Publication: 2023 Jun 19 (Print Publication: 2023). |
| نوع المنشور: | Review; Meta-Analysis; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Instituto de Ensino e Pesquisa Albert Einstein Country of Publication: Brazil NLM ID: 101281800 Publication Model: eCollection Cited Medium: Internet ISSN: 2317-6385 (Electronic) Linking ISSN: 16794508 NLM ISO Abbreviation: Einstein (Sao Paulo) Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: São Paulo, SP : Instituto de Ensino e Pesquisa Albert Einstein |
| مواضيع طبية MeSH: | Neoplasms*/epidemiology , HIV Infections*/complications , HIV Infections*/drug therapy , HIV Infections*/epidemiology, Humans ; Aged ; HIV ; Aging ; Anti-Retroviral Agents |
| مستخلص: | Introduction: The human immunodeficiency virus (HIV) pandemic remains an important issue. In 2020, approximately 37.7 million people were living with the disease and there were more than 680 thousand deaths due to complications linked to the disease. Despite these exorbitant numbers, the introduction of highly active antiretroviral therapy has marked a new era, changing the epidemiological profile of the infection and related pathologies, including neoplasms. Objective: We performed a literature review to assess the role of neoplasms in patients with HIV after the introduction of antiretroviral therapy. Methods: A literature review was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) method, searching the MEDLINE, LILACS, and COCHRANE databases for articles published from 2010 onwards. Results: Using specific key terms, 1,341 articles were identified; two were duplicates, 107 were selected for full-text evaluation, and 20 were included in the meta-analysis. The selected studies included 2,605,869 patients. Fifteen of the 20 articles indicated a reduction in the global incidence of AIDS-defining neoplasms and 12 indicated an overall increase in non-AIDS-defining cancers after the introduction of antiretrovirals. This growth trend could be explained by a range of factors including the aging population with HIV, risky behaviors, and coinfection with oncogenic viruses. Conclusions: There was a decreasing trend in the incidence of AIDS-defining neoplasms and increasing trend in non-AIDS-defining neoplasms. However, the carcinogenic effect of antiretrovirals could not be confirmed. In addition, studies focusing on the oncogenic role of HIV and screening for neoplasms in individuals with HIV are required. |
| References: | Cancer. 2004 Jul 15;101(2):317-24. (PMID: 15241829) Eur J Cancer. 2009 Apr;45(6):1028-41. (PMID: 19091549) Br J Cancer. 2010 Jul 27;103(3):416-22. (PMID: 20588274) Arch Intern Med. 2010 Aug 9;170(15):1337-45. (PMID: 20696958) Trends Pharmacol Sci. 2002 Aug;23(8):381-8. (PMID: 12377580) Lancet Oncol. 2003 Sep;4(9):537-47. (PMID: 12965274) AIDS Care. 2015;27(7):860-9. (PMID: 25714364) J Natl Cancer Inst. 2011 May 4;103(9):753-62. (PMID: 21483021) Int J STD AIDS. 2017 Oct;28(12):1190-1198. (PMID: 28178892) Indian J Med Res. 2016 May;143(Supplement):S129-S135. (PMID: 27748287) J Clin Oncol. 2009 Feb 20;27(6):884-90. (PMID: 19114688) Arch Pathol Lab Med. 2020 May;144(5):572-579. (PMID: 31460770) Clin Infect Dis. 2013 Sep;57(5):756-64. (PMID: 23735330) World J Virol. 2015 Aug 12;4(3):209-18. (PMID: 26279983) Int J Cancer. 2010 Sep 1;127(6):1437-45. (PMID: 20049835) Rev Inst Med Trop Sao Paulo. 2011 Nov-Dec;53(6):309-14. (PMID: 22183453) AIDS. 2014 Sep 10;28(14):2109-18. (PMID: 25265077) Clin Infect Dis. 2009 Oct 1;49(7):1109-16. (PMID: 19705973) J Surg Oncol. 2010 Sep 1;102(3):282-6. (PMID: 20740588) Eur Rev Med Pharmacol Sci. 2012 Oct;16(10):1377-88. (PMID: 23104654) Cancer Res. 2003 Oct 1;63(19):6556-62. (PMID: 14559851) Indian J Sex Transm Dis AIDS. 2021 Jul-Dec;42(2):118-124. (PMID: 34909615) AIDS. 2010 Jul 31;24(12):1877-86. (PMID: 20588170) Lancet HIV. 2017 Nov;4(11):e495-e504. (PMID: 28803888) J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):414-20. (PMID: 23274934) Lancet. 1998 Jun 20;351(9119):1833-9. (PMID: 9652666) Curr Opin HIV AIDS. 2017 Jan;12(1):6-11. (PMID: 27749369) AIDS. 2010 Mar 13;24(5):697-706. (PMID: 20177360) Int J Cancer. 2012 Jun 15;130(12):2990-6. (PMID: 21796633) Clin Infect Dis. 2009 Mar 1;48(5):609-11. (PMID: 19191648) Cancer. 2005 Oct 1;104(7):1505-11. (PMID: 16104038) J Clin Epidemiol. 2009 Oct;62(10):e1-34. (PMID: 19631507) Clin Infect Dis. 2011 Jun 15;52(12):1458-65. (PMID: 21628488) J Infect Public Health. 2015 Jan-Feb;8(1):1-10. (PMID: 25294086) Antimicrob Agents Chemother. 2019 May 24;63(6):. (PMID: 30962341) Cancer. 2011 Mar 1;117(5):1089-96. (PMID: 20960504) AIDS Res Hum Retroviruses. 2015 May;31(5):514-8. (PMID: 25417712) HIV Med. 2013 Feb;14(2):77-84. (PMID: 22934689) Ann Intern Med. 2021 Jun;174(6):768-776. (PMID: 33721519) Health Technol Assess. 2000;4(10):1-115. (PMID: 10932019) Semin Oncol. 2016 Feb;43(1):173-188. (PMID: 26970136) J Natl Cancer Inst. 2005 Mar 16;97(6):425-32. (PMID: 15770006) Clin Cancer Res. 2007 Sep 1;13(17):5183-94. (PMID: 17785575) Br J Dermatol. 2010 Jun;162(6):1269-77. (PMID: 20184584) BMC Cancer. 2017 Apr 14;17(1):270. (PMID: 28410587) BMC Infect Dis. 2013 Oct 09;13:471. (PMID: 24106926) |
| المشرفين على المادة: | 0 (Anti-Retroviral Agents) |
| تواريخ الأحداث: | Date Created: 20230621 Date Completed: 20230622 Latest Revision: 20230701 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10247279 |
| DOI: | 10.31744/einstein_journal/2023RW0231 |
| PMID: | 37341221 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2317-6385 |
|---|---|
| DOI: | 10.31744/einstein_journal/2023RW0231 |